NewAmsterdam Pharma Company N.V.
NASDAQ:NAMSBiotechnology
+$0.12 today
- Market cap
- $2.37B
- Beta
- 0.08
- P/E (TTM)
- -17.2
- EPS (TTM)
- -$1.76
Volume 1.80M
Average 1.21M
NAMS Net Income
Bottom-line profit after all expenses, interest, and taxes.
NewAmsterdam Pharma Company N.V.NASDAQ: NAMS
Net Income · Q2 FY2026 · quarter ended Jun 2026
Net income remains negative
Q2 FY2026 net income was -$64.14M, compared with -$17.36M a year earlier. Trailing-twelve-month net income was -$259.5M.
Context
- Net income amounted to 905.7% of revenue in FY2025, up 375.5 pp from a year earlier.
- Net income grew in size in 2 of the last 3 fiscal years.
What to watch
Whether net income reaches the consensus estimate from 10 analysts of -$185.78M (+8.9%) for the fiscal year ending Dec 2026, a slowdown from the +15.6% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- -$64.14M-32.4% QoQ
- Last fiscal yearDec 2025
- -$203.82M+15.6% YoY
- LTMJun 2026
- -$259.5M-56.6% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -269.4% | +18.7% | +288.0 pp |
| 1 year | +15.6% | +8.9% | -6.8 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the income statement
- Latest · FY2025
- (203.82M) USD
- Year-over-year change
- +15.6%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (203.82M) | +15.6% |
| FY2024 | 2024-12-31 | (241.6M) | -36.5% |
| FY2023 | 2023-12-31 | (176.94M) | -681.7% |
| FY2022 | 2022-12-31 | (22.63M) | +45.8% |
| FY2021 | 2021-12-31 | (41.79M) | — |
Net Income vs competitors
How NAMS compares with its peers on the latest reported figures
- Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -56.6% is the 8th highest of 9, against a peer median of -8.0%.
- Net income amounts to 3644.2% of revenue for NAMS, versus a peer median of 223.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| FY2025 | -A$12.15M AUD | +36.5% | — | 223.4% | |
SEPNSepterna, Inc. | LTM Sep 2026 | -$59M USD | -0.3% | — | 61.3% |
BIOABioAge Labs, Inc. | LTM Mar 2026 | -$89.93M USD | -26.6% | — | 871.8% |
| LTM Mar 2026 | -$113.28M USD | +2.6% | — | — | |
| LTM Sep 2026 | -$163.2M USD | -9.3% | — | — | |
| LTM Jun 2026 | -$259.5M USD | -56.6% | — | 3644.2% | |
| LTM Jun 2026 | -$325.1M USD | -15.3% | — | 25.3% | |
| LTM Jun 2026 | -$511.45M USD | -6.8% | — | 14191.2% | |
| LTM Jun 2026 | -$534.8M USD | -211.7% | — | — | |
| Peer median (excluding NAMS) | — | -8.0% | — | 223.4% | |
Competitors are the stored peer set for NAMS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 102.69M | 14.09M | 45.56M | 22.5M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 59K |
| Gross Profit | 0 | 102.69M | 14.09M | 45.56M | 22.44M |
| Gross Margin | — | 100.0% | 100.0% | 100.0% | 99.7% |
| Research & Development | 28.97M | 86.74M | 159.42M | 151.41M | 141.83M |
| Selling, General & Admin | 5.68M | 19.51M | 37.63M | 70.45M | 106.3M |
| Operating Expenses | 34.98M | 106.25M | 197.06M | 221.85M | 248.13M |
| Depreciation & Amortization | 5K | 9K | 49K | 113K | 220K |
| EBITDA | (41.37M) | (22.34M) | (176.86M) | (241.49M) | (242.33M) |
| EBITDA Margin | — | -21.8% | -1255.2% | -530.0% | -1076.9% |
| Operating Income | (34.98M) | (3.56M) | (182.97M) | (176.29M) | (225.68M) |
| Operating Margin | — | -3.5% | -1298.6% | -386.9% | -1002.9% |
| Interest Income | 0 | 0 | 10.22M | 16.88M | 27.59M |
| Interest Expense | 411K | 287K | 6.8M | 0 | 0 |
| Other Income / Expenses | (6.81M) | (19.08M) | 6.06M | (65.31M) | 21.86M |
| Income Before Tax | (41.79M) | (22.63M) | (176.91M) | (241.6M) | (203.82M) |
| Pre-Tax Margin | — | -22.0% | -1255.6% | -530.3% | -905.7% |
| Income Tax Expense | 0 | 0 | 27K | (1K) | 0 |
| Net Income | (41.79M) | (22.63M) | (176.94M) | (241.6M) | (203.82M) |
| Net Margin | — | -22.0% | -1255.8% | -530.3% | -905.7% |
| EPS (Basic) | (3.34) | (1.19) | (2.15) | (2.56) | (1.75) |
| EPS (Diluted) | (3.34) | (1.19) | (2.15) | (2.56) | (1.75) |
| Weighted Avg Shares | 17.75M | 18.97M | 82.16M | 94.36M | 114.4M |
| Weighted Avg Shares (Diluted) | 17.75M | 18.97M | 82.16M | 94.36M | 114.4M |
NewAmsterdam Pharma Company N.V.
NASDAQ:NAMS
Intrinsic Alpha fair value
Locked
Current Price
$19.74
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.